|1.||Banks, Lawrence: 13 articles (07/2015 - 06/2004)|
|2.||Münger, Karl: 7 articles (06/2012 - 11/2002)|
|3.||Thomas, Miranda: 6 articles (07/2015 - 07/2008)|
|4.||Wei, Wenyi: 6 articles (01/2015 - 11/2011)|
|5.||Pawlita, Michael: 6 articles (01/2013 - 05/2002)|
|6.||Neckers, Len: 6 articles (10/2012 - 04/2002)|
|7.||Pim, David: 5 articles (07/2015 - 06/2010)|
|8.||Massimi, Paola: 5 articles (07/2015 - 06/2004)|
|9.||Cleveland, John L: 5 articles (08/2014 - 02/2004)|
|10.||Zwerschke, Werner: 5 articles (05/2014 - 12/2005)|
12/19/2005 - "The molecular knowledge gained so far from studying EWS-ETS oncoproteins has not only broadened our understanding of Ewing tumors but also improved the diagnosis of these highly undifferentiated tumors. "
03/01/1996 - "Actuarial 5-year disease-free and overall survival for p53(-)/neu(-) tumors were 88% and 97%, respectively, versus 50% and 66%, for tumors overexpressing one or both oncoproteins (p=0.004)."
05/01/1993 - "The phenomenon of preferential oncogene or oncogene protein expression in certain morphologic types of tumor may help to better define the biologic behavior and aggressiveness of a given tumor, so leading to advances in the diagnosis, treatment, and understanding of human neoplasia."
03/05/2010 - "Accumulating studies have uncovered various molecular mechanisms by which oncoproteins affect cellular metabolism, raising a concern as to whether targeting glycolysis will be equally effective in treating cancers arising from different oncogenic activities. "
01/01/2014 - "The potential efficacy of knocking down the key alterations in cervical cancer - E6 and E7 human papillomavirus oncoproteins - must not be overlooked. "
02/01/2008 - "The results of this study broaden the insight into the relationships shared among oncoproteins and the antioxidant defense system, and this could be helpful in the clinical management of esophageal carcinoma."
01/01/2006 - "The aim of this study was to investigate the expression of bcl-2 and p53 oncoproteins in a series of transitional cell bladder carcinomas and its relation to traditional prognostic indicators and patients' survival. "
05/19/2000 - "Previous studies have identified two viral oncoproteins E6 and E7, which are expressed in the majority of HPV-associated carcinomas. "
01/01/1999 - "Previous studies have identified two viral oncoproteins, E6 and E7, which are expressed in the majority of HPV-associated carcinomas. "
12/01/1998 - "In this study, the authors analyzed the effects of high doses of gamma irradiation on the expression of E6/E7 oncoproteins in HPV-16-infected cervical carcinoma cell lines. "
06/01/2015 - "The potential efficacy of knocking down the key alterations in CC, E6 and E7 human papilloma virus oncoproteins must not be overlooked."
04/01/2007 - "In this study we have investigated the immunologic crossreactivity between murine tumour cell lines expressing human papilloma virus (HPV) 16-derived E6/E7 oncoproteins with distinct surface expression of MHC class I molecules. "
03/01/1992 - "The oncogene products were detected in 17(70.8%) of the 24 oral papillomas under study. "
01/01/1992 - "Immunohistochemical study of ras and myc oncoproteins in apocrine breast lesions with and without papillomatosis."
09/01/2015 - "Transcriptomic analyses of genes differentially expressed by high-risk and low-risk human papilloma virus E6 oncoproteins."
|4.||Breast Neoplasms (Breast Cancer)
06/01/1995 - "Approximately one fifth of the breast cancer patients in this analysis (disease-free and recurrent) expressed only a single oncogene marker (c-fos, c-myc, Ha-ras, or p53); one quarter of patients with recurrent disease expressed only one oncogene protein. "
11/01/1995 - "This study explores the relationship between expression of these oncoproteins and clinical outcome in 92 patients with either locally advanced or metastatic breast cancer treated with primary endocrine therapy. "
11/15/2015 - "Mouse models of metastatic breast cancer typically feature mutated oncoproteins that activate PI3K, Stat3, and Ras signaling, but the individual and combined roles of these pathways in breast cancer progression are poorly understood. "
06/01/2014 - "Ganetespib is a small molecule, nongeldanamycin HSP90 inhibitor with potent inhibitory effects on HSP90-dependent oncoproteins of relevance to breast cancer pathogenesis. "
01/01/2013 - "The ERRs also modulate breast cancer cell metabolism, growth and proliferation through the regulation of key oncoproteins. "
01/01/2000 - "HIF-1alpha is overexpressed in the majority of common human cancers and their metastases, due to the presence of intratumoral hypoxia and as a result of mutations in genes encoding oncoproteins and tumor suppressors. "
01/01/2012 - "Heat shock proteins (hsps) are induced in response to hypoxia, provide cancer cells with protection against tumour-associated stressors and chaperone oncoproteins that drive tumour proliferation. "
12/01/2012 - "Plasminogen activator inhibitor-1 (PAI-1) expression in relation to hypoxia and oncoproteins in clinical cervical tumors."
08/01/1997 - "We hypothesize that oncogene products either stimulate HIF-1 and related factors or, in the case of c-Myc, directly activate hypoxia/glucose responsive elements in glycolytic enzyme genes to increase the ability of cancer cells to undergo aerobic glycolysis."
07/01/2013 - "Cancer cells are in a constant state of proteotoxic stress and exploit the HSPs to protect themselves against the toxic effects of aberrant oncoproteins, genomic instability, hypoxia, and acidosis. "
|1.||Epidermal Growth Factor (EGF)
|2.||Epidermal Growth Factor Receptor (EGF Receptor)
|4.||Messenger RNA (mRNA)
|5.||Tumor Viral Antigens (Large T Antigen)
|6.||Heat-Shock Proteins (Heat-Shock Protein)
|10.||Proteins (Proteins, Gene)
|3.||Drug Therapy (Chemotherapy)
|4.||Heterologous Transplantation (Xenotransplantation)